Home  /  Resource Library  /  POLARIX: How does MYC and BCL2 expression impact outcomes post frontline treatment with PV in DLBCL

POLARIX: How does MYC and BCL2 expression impact outcomes post frontline treatment with PV in DLBCL

Video interview with Gilles Salles, MD who discusses the impact of MYC and BCL2 expression on the use of front line treatement of diffuse large b-cell lymphoma with polatuzumab vedotin based therapy.